This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0D0AP_M.jpgWASHINGTON (Reuters) – Swiss drugmaker Roche (S:) has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics (O:), the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker’s push into treating rare diseases including hemophilia A.
The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the planned merger complies with antitrust law, the agency said in a statement.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.